NeuroSearch announces the date for its third quarter 2008 interim report and related telephone conference

Investor News                                                                   


--------------------------------------------------------------------------------
| NeuroSearch announces the date for its third quarter 2008 interim report and |
| related telephone conference                                                 |
--------------------------------------------------------------------------------
| NeuroSearch's interim report for the third quarter 2008 will be on the       |
| agenda of a board meeting scheduled for 17 November 2008 and be released     |
| immediately hereafter.                                                       |
| On the same day, a telephone conference will be held at 3 pm Copenhagen time |
| (2 pm London time, 9 am New York time). Flemming Pedersen, CEO, Anita        |
| Milland, Vice President, CFO and Hanne Leth Hillman, Vice President,         |
| Director of IR & Corporate Communications, will present the interim report   |
| and answer questions. The telephone conference will be conducted in English  |
| and the telephone number is +44 (0)20 7162 0077. The corresponding           |
| PowerPoint presentation will be available at www.neurosearch.com after the   |
| release of the report.                                                       |
--------------------------------------------------------------------------------
| Contact person:                                                              |
--------------------------------------------------------------------------------
| Hanne Leth Hillman Vice President, Director of IR & Corporate                |
| Communications, telephone: +45 4017 5103                                     |
--------------------------------------------------------------------------------
| NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on     |
| Nasdaq OMX Copenhagen. The company's core business covers the development of |
| novel drugs, based on a broad and well-established drug discovery platform   |
| focusing on ion channels and CNS disorders. A substantial share of its       |
| activities is partner financed through a broad alliance with GlaxoSmithKline |
| (GSK) and collaborations with, among others, Abbott and Astellas.            |
| NeuroSearch's drug pipeline comprises 14 clinical (Phase I-III) development  |
| programmes: ACR16 for Huntington's disease (Phase III), tesofensine for      |
| obesity and in Type 2 diabetes (Phase III in preparation), NS2359 for        |
| depression (Phase II) and ADHD (Phase II) in partnership with GSK, ABT-894   |
| for ADHD (Phase II) and pain (Phase II) in partnership with Abbott, ACR16    |
| for schizophrenia (Phase I) in partnership with Astellas, ACR325 for         |
| Parkinson's disease (Phase II in preparation) and bipolar disorder (Phase II |
| in preparation), ABT-107 and ABT-560 for the treatment of various CNS        |
| disorders - both (Phase I) in collaboration with Abbott, NSD-644 for         |
| pain (Phase I) in partnership with GSK, ACR343 for Parkinson's disease       |
| (Phase I) and NSD-788 for anxiety/depression (Phase I). In addition,         |
| NeuroSearch has a broad portfolio of preclinical drug candidates and holds   |
| equity interests in several biotech companies.                               |
--------------------------------------------------------------------------------